Wall Street Trims Ratings for Novo Nordisk Stock, as Ozempic's Competition Grows -- Barrons.com
Viking Therapeutics (NasdaqCM:VKTX) Completes Enrollment For Phase 2 Trial Of VK2735
H.C. Wainwright Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $102
Earnings Preview: VKTX to Report Financial Results Post-market on April 23
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know
SA Asks: What's the Best Weight-loss Drug Stock Right Now?
Why Did Lilly Data for Oral Obesity Drug Boost Structure and Metsera?
Express News | HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $102 Price Target
Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide
Viking Therapeutics Analyst Ratings
SA Analyst Upgrades: AMD, PLTR, VKTX, HUBS, MO, USB, SFIX, VERV
Today's Pre-Market Movers and Top Ratings | TSM, LLY, UNH and More
US stocks volatility | Eli Lilly and Co (LLY.US) surged 13% in pre-market trading after positive results from the phase 3 trial of its oral weight loss medication.
The Eli Lilly and Co trial showed that the oral medication orforglipron reduces body weight by nearly 8% in patients with type 2 diabetes at the highest dosage, and it also lowers blood sugar.
Express News | Shares of Obesity Drug Developer Viking Therapeutics Falls 5.3% Premarket After Eli Lilly's Pill Leads to Weight Loss in Late-Stage Trial
Viking Therapeutics Slips After Eli Lilly Reports Orforglipron Trial Results
Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025
Viking Therapeutics' VK2735 Gains Buy Rating Amid Pfizer's GLP-1 Drug Halt and Promising Trial Results
Pfizer (PFE.US) facing setbacks in research sparks acquisition speculation, stocks of the new weight loss drug rising sharply.
Pfizer (PFE.US) has stopped the development of the highly anticipated oral weight loss drug Danuglipron. Investors are betting that this setback may prompt Pfizer to seek acquisition trades, leading to a rise in the stock prices of several biotechnology companies developing weight loss drugs on Monday.
Nasdaq, S&P, and Dow Closed Higher as Trump Temporarily Shields Tech Sector From Tariffs
Viking Therapeutics Shares Are Trading Higher After Pfizer Discontinued the Development of Danuglipron.